| Revista: | Revista de investigación clínica |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000453007 |
| ISSN: | 0034-8376 |
| Autors: | Şimşek, Barış1 İnan, Duygu2 Çınar, Tufan3 Cagdas Yumurtaş, Ahmet1 Ozan Tanık, Veysel4 Zeren, Gonul1 İlker Avcı, İlhan1 Yücel Karabay, Can1 Güngör, Barış1 Tokgozoğlu, Lale5 |
| Institucions: | 1Health Sciences University, Dr. Siyami Ersek Training and Research Hospital, Estambul. Turquía 2Basaksehir Cam and Sakura Training and Research Hospital, Department of Cardiology, Estambul. Turquía 3Health Sciences University, Sultan II Abdülhamid Han Training and Research Hospital, Estambul. Turquía 4Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara. Turquía 5Hacettepe Medical Faculty, Ankara. Turquía |
| Any: | 2021 |
| Període: | Nov-Dic |
| Volum: | 73 |
| Número: | 6 |
| Paginació: | 371-378 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Aplicado, descriptivo |
| Resumen en inglés | High-intensity statin (HIS) therapy is widely recommended for secondary prevention after an acute myocardial infarction (AMI). The 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) dyslipidemia guidelines have lowered the target low-density lipoprotein cholesterol (LDL-C) level, which necessitates a more frequent use of non-statin therapies. Objectives: The objectives of the study were to investigate the rate of LDL-C target attainment for secondary prevention in AMI patients. Methods: This retrospective investigation included 1360 patients diagnosed with AMI in a tertiary heart center. Lipid parameters were collected within 24 h of admission and within 1 year after discharge. The medications used were retrieved from medical records, and the lowest LDL-C levels after statin treatment were used to assess the effectiveness of the therapy. LDL-C target attainment was defined according to the 2016 ESC/EAS dyslipidemia guidelines as an LDL-C level of < 70 mg/dL and a ≥ 50% reduction from baseline. In addition, the rate of LDL-C target attainment according to the 2019 ESC/EAS guidelines was defined as an LDL-C level of < 55 mg/dL and a ≥ 50% reduction from baseline. Results: In total, 502 (36.9%) and 247 (18.2%) patients reached the LDL-C targets according to the 2016 and 2019 ESC/EAS guidelines, respectively. The admission LDL-C levels were significantly lower and HIS treatment was used more frequently in patients who subsequently attained the LDL-C goal. Remarkably, 461 (34%) patients failed to reach the LDL-C goals despite HIS treatment. Only 27 (1.9%) patients were prescribed ezetimibe. Conclusion: The rate of LDL-C goal attainment in AMI patients was low, which indicates the need for combination statin and non-statin lipid-lowering therapies |
| Disciplines | Medicina |
| Paraules clau: | Sistema cardiovascular, Metabolismo y nutrición, Infarto agudo del miocardio, Estatinas, Colesterol, Lipoproteínas de baja densidad, Guías terapéuticas |
| Keyword: | Cardiovascular system, Metabolism and nutrition, Acute myocardial infarction, Statins, Cholesterol, Low density lipoproteins, Therapeutic guides |
| Text complet: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
